New Magazine Offers In-Depth Financing Data and Insights on
Medical Device and Drug Approvals
DENVER–(BUSINESS WIRE)–#cobioscience—Colorado
BioScience Association (CBSA) today launched the new issue of its
annual magazine, BioScience Colorado: Collaborative by Nature, at
this week’s 2019 BIO International Convention in Philadelphia. The
2019-2020 magazine highlights Colorado’s reputation for collaboration,
profiles companies focused on engaging patients in the product design
and development process, and details the successes of the
state-supported Advanced Industries grant program.
Jennifer Jones Paton, President and CEO of CBSA, says:
“Colorado’s
life science ecosystem stands apart because of our commitment to solving
business challenges together. Our member companies, academic and
research institutions, and partners collaborate to improve the lives of
patients here in Colorado and around the world. We titled our new
BioScience Colorado magazine Collaborative by Nature because of the
close working relationships in our ecosystem.”
BioScience Colorado 2019-2020: Collaborative by Nature provides
comprehensive data on the state’s life science industry, with detailed
information on topics of interest.
Advanced Industry Grants
Since inception, the state
funded Advanced Industries Grant program has awarded 413 grants to life
science companies, creating 773 direct jobs, 79 new companies and $551.7
million in follow-on grants and investments.
Financing
Colorado life science companies raised $1
billion in 2018. The magazine breaks down investments by company name
and deal type.
Medical Device Approvals
In 2018, 219 medical devices
and diagnostics developed by Colorado companies received 510(K) approval
from the FDA, and 5 achieved a PMA designation. In-vitro diagnostics,
cardiovascular, and orthopedics were the largest categories of medical
devices in approved or investigational status.
Pharmaceutical Trials by Therapy Area
Colorado
pharmaceutical companies participated in 1,140 clinical trials in 2018.
Top drugs and trials by therapy area included: Oncology, central nervous
system and infectious disease.
Emily Roberts, Vice President of CBSA, says:
“The annual
magazine provides new insights on the breakthroughs happening here and
in-depth information on recent investments, grants, drug and device
trials, and product approvals. CBSA Members and partners use the annual
magazine to share our life science success stories with prospective
investors, potential partners and out-of-state talent considering a move
to Colorado.”
CBSA members will receive a copy of the magazine via mail. Additional
copies are available at any CBSA event or by request. An electronic
version of the magazine is available on the CBSA website.
About the Colorado BioScience Association
Colorado BioScience Association champions life science. We serve as the
hub of Colorado’s thriving bioscience sector by connecting innovators to
funding, infrastructure, research and talent. From promising young
companies to established corporations and institutions, we provide
opportunities for networking, education and professional development. We
grow the bioscience workforce and lead business expansion policies to
advance the industry in our state. CBSA represents more than 350 member
organizations, including biotechnology, pharmaceutical, medical device,
diagnostic, ag bio and mobile digital health companies, research and
academic institutions and service providers. Learn more about us at http://www.cobioscience.com.
Connect with CBSA: Twitter @COBioscience, Facebook
and LinkedIn.
Contacts
Sheliah Reynolds
Primavera Group for Colorado BioScience Association
(720)
289-4739
sheliah@theprimaveragroup.com